GPhA Warns FDA On ANDA Review Transparency
User fee negotiations could be 'lengthy and very detailed' unless FDA does 'the right thing' and implements 'effective' communication practices, generic trade group says.
User fee negotiations could be 'lengthy and very detailed' unless FDA does 'the right thing' and implements 'effective' communication practices, generic trade group says.